Home › Companies › Acadia Pharmaceuticals Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Acadia Pharmaceuticals Inc.’s Form 8-K, filed May 29, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 29, 2026: 5 items on Acadia Pharmaceuticals Inc.’s Form 8-K, filed May 29, 2026: 2 approved · 3 passed (calculated).
Notable dissent: 2 directors (14.6%, 10.6% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Acadia Pharmaceuticals Inc. in the interactive database Compare manager voting policies
These tallies are Acadia Pharmaceuticals Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: James M. Daly | 146,927,745 | -- | -- | 3,521,002 | 10,356,394 | 98% | Passed (calculated) | — |
| Elect Director: Edmund P. Harrigan, M.D. | 128,460,130 | -- | -- | 21,988,617 | 10,356,394 | 85% | Passed (calculated) | — |
| Elect Director: Adora Ndu, Pharm.D., J.D. | 134,540,552 | -- | -- | 15,908,195 | 10,356,394 | 89% | Passed (calculated) | — |
| The approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, which | 148,265,173 | 1,911,358 | 272,216 | -- | 10,356,394 | 99% | Approved | — |
| The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, which | 157,409,378 | 3,319,736 | 76,027 | -- | -- | 98% | Approved | — |
Source: Acadia Pharmaceuticals Inc., Form 8-K, filed with the SEC on May 29, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
378 asset managers disclosed a vote on at least one Acadia Pharmaceuticals Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Acadia Pharmaceuticals Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Adora Ndu, Pharm.D., J.D.
Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Adora Ndu, Pharm.D., J.D.”): 134,540,552 for, 15,908,195 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 95 asset managers below reported 46,825,265 for, 6,831,662 withheld, 67 abstained, 88,571 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 14,866,415 | 0 | 0 | 0 | For |
| Vanguard | 14,719,012 | 0 | 67 | 19,592 | For |
| State Street | 19,688 | 0 | 0 | 5,634,644 | Withhold |
| Fidelity | 3,475,543 | 0 | 0 | 0 | For |
| First Trust | 3,177,047 | 0 | 0 | 0 | For |
| TIAA | 1,141,112 | 0 | 0 | 0 | For |
| Charles Schwab | 1,051,680 | 0 | 0 | 0 | For |
| Dimensional | 1,000,882 | 0 | 0 | 0 | For |
| MFS | 621,810 | 0 | 0 | 0 | For |
| Invesco | 609,164 | 0 | 0 | 0 | For |
| John Hancock | 542,429 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 537,427 | 0 | 0 | 0 | For |
| Voya | 445,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 426,213 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 419,234 | Withhold |
| GLENMEDE FUND INC | 365,176 | 0 | 0 | 0 | For |
| Equitable | 178,870 | 0 | 0 | 101,000 | Mixed |
| Bridge Builder Trust | 279,264 | 0 | 0 | 0 | For |
| Jackson National | 230,730 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 203,782 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 180,000 | 0 | 0 | 0 | For |
| Prudential/PGIM | 164,947 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 162,935 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 158,292 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 149,600 | 0 | 0 | 0 | For |
Showing the 25 largest of 95 asset managers. All 95 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Edmund P. Harrigan, M.D.
Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Edmund P. Harrigan, M.D.”): 128,460,130 for, 21,988,617 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 95 asset managers below reported 37,850,514 for, 15,646,380 withheld, 100 abstained, 88,571 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 514,584 | 0 | 0 | 14,351,831 | Withhold |
| Vanguard | 14,702,586 | 0 | 100 | 35,985 | For |
| State Street | 5,646,482 | 0 | 0 | 7,850 | For |
| Fidelity | 3,421,607 | 0 | 0 | 53,936 | For |
| First Trust | 3,177,047 | 0 | 0 | 0 | For |
| TIAA | 1,141,112 | 0 | 0 | 0 | For |
| Charles Schwab | 1,051,680 | 0 | 0 | 0 | For |
| Dimensional | 1,000,882 | 0 | 0 | 0 | For |
| MFS | 621,810 | 0 | 0 | 0 | For |
| Invesco | 609,164 | 0 | 0 | 0 | For |
| John Hancock | 542,429 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 537,427 | 0 | 0 | 0 | For |
| Voya | 445,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 426,213 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 419,234 | Withhold |
| GLENMEDE FUND INC | 365,176 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 279,870 | Withhold |
| Bridge Builder Trust | 255,128 | 0 | 0 | 24,136 | Mixed |
| Jackson National | 230,730 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 203,782 | Withhold |
| Prudential/PGIM | 164,947 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 162,935 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 158,292 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 149,600 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 133,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 95 asset managers. All 95 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: James M. Daly
Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: James M. Daly”): 146,927,745 for, 3,521,002 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 95 asset managers below reported 52,774,603 for, 722,375 withheld, 16 abstained, 88,571 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 14,866,415 | 0 | 0 | 0 | For |
| Vanguard | 14,702,670 | 0 | 16 | 35,985 | For |
| State Street | 5,646,482 | 0 | 0 | 7,850 | For |
| Fidelity | 3,475,543 | 0 | 0 | 0 | For |
| First Trust | 3,177,047 | 0 | 0 | 0 | For |
| TIAA | 1,141,112 | 0 | 0 | 0 | For |
| Charles Schwab | 1,051,680 | 0 | 0 | 0 | For |
| Dimensional | 1,000,882 | 0 | 0 | 0 | For |
| MFS | 621,810 | 0 | 0 | 0 | For |
| Invesco | 609,164 | 0 | 0 | 0 | For |
| John Hancock | 542,429 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 537,427 | 0 | 0 | 0 | For |
| Voya | 445,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 426,213 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 419,234 | Withhold |
| GLENMEDE FUND INC | 365,176 | 0 | 0 | 0 | For |
| Equitable | 178,870 | 0 | 0 | 101,000 | Mixed |
| Bridge Builder Trust | 279,264 | 0 | 0 | 0 | For |
| Jackson National | 230,730 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 203,782 | 0 | 0 | 0 | For |
| Prudential/PGIM | 164,947 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 162,935 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 158,292 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 149,600 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 133,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 95 asset managers. All 95 are in the interactive database (link above).
99.2% of fund votes cast · no official result
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 5,209,670 SHARES.
The 94 asset managers below reported 53,079,115 for, 405,344 against, 16,375 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 14,866,415 | 0 | 0 | 0 | For |
| Vanguard | 14,702,637 | 36,034 | 0 | 0 | For |
| State Street | 5,646,194 | 8,138 | 0 | 0 | For |
| Fidelity | 3,475,543 | 0 | 0 | 0 | For |
| First Trust | 3,177,047 | 0 | 0 | 0 | For |
| TIAA | 1,141,112 | 0 | 0 | 0 | For |
| Charles Schwab | 1,051,680 | 0 | 0 | 0 | For |
| Dimensional | 1,000,882 | 0 | 0 | 0 | For |
| MFS | 621,810 | 0 | 0 | 0 | For |
| Invesco | 609,164 | 0 | 0 | 0 | For |
| John Hancock | 542,429 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 537,427 | 0 | 0 | 0 | For |
| Voya | 445,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 426,213 | 0 | 0 | 0 | For |
| T. Rowe Price | 419,234 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 365,176 | 0 | 0 | 0 | For |
| Equitable | 279,870 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 279,264 | 0 | 0 | 0 | For |
| Jackson National | 230,730 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 203,782 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 0 | 180,000 | 0 | 0 | Against |
| Prudential/PGIM | 164,947 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 162,935 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 158,292 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 149,600 | 0 | 0 | 0 | For |
Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).
Combines 14 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 98.1% for (May 29, 2025 meeting) ▲ 0.7 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.
Acadia Pharmaceuticals Inc.’s own tally for this item (“the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, which was approved by the following vote”): 148,265,173 for, 1,911,358 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “In addition to the election of three Class I directors, the following matters were submitted to a vote of the stockholders at the Annual Meeting: (i) the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, which was app…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 14,866,415 | 0 | 0 | 0 | For |
| Vanguard | 14,738,663 | 7 | 1 | 0 | For |
| State Street | 5,654,332 | 0 | 0 | 0 | For |
| Fidelity | 3,475,543 | 0 | 0 | 0 | For |
| First Trust | 3,177,047 | 0 | 0 | 0 | For |
| TIAA | 1,141,112 | 0 | 0 | 0 | For |
| Charles Schwab | 1,051,680 | 0 | 0 | 0 | For |
| Dimensional | 1,000,882 | 0 | 0 | 0 | For |
| MFS | 621,810 | 0 | 0 | 0 | For |
| Invesco | 609,164 | 0 | 0 | 0 | For |
| John Hancock | 542,429 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 537,427 | 0 | 0 | 0 | For |
| Voya | 445,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 426,213 | 0 | 0 | 0 | For |
| T. Rowe Price | 419,234 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 365,176 | 0 | 0 | 0 | For |
| Equitable | 279,870 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 279,264 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 253,402 | 0 | 0 | 0 | For |
| Jackson National | 230,730 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 203,782 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 0 | 0 | 180,000 | 0 | Abstain |
| Prudential/PGIM | 164,947 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 162,935 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 158,292 | 0 | 0 | 0 | For |
Fund voting reports, all 93 managers: 53,472,664 for, 90,323 against, 196,376 abstained, 88,571 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 43,102,442 | 0 | 0 | 0 | For |
| State Street | 8,199,285 | 4,276 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 7,144,524 | 0 | 0 | 0 | For |
| BlackRock | 4,926,437 | 2,134 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,466,247 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 2,864,096 | 0 | 0 | 0 | For |
| Point72 | 1,975,507 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,839,632 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 1,438,198 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,083 | 0 | 0 | 0 | For |
| Nuveen | 1,163,143 | 0 | 0 | 0 | For |
| Artisan | 1,156,870 | 0 | 0 | 0 | For |
| Logos Global Management LP | 1,147,084 | 0 | 0 | 0 | For |
| Northern Trust | 1,110,186 | 0 | 0 | 0 | For |
| Vanguard | 1,076,129 | 0 | 0 | 0 | For |
| WEATHERBIE CAPITAL, LLC | 1,005,974 | 0 | 0 | 0 | For |
| Allspring | 990,027 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 935,406 | 0 | 0 | 0 | For |
| ROCKEFELLER FINANCIAL LLC | 906,755 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 897,318 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 839,951 | 0 | 0 | 0 | For |
| T. Rowe Price | 834,569 | 0 | 0 | 0 | For |
| Renaissance | 811,095 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 769,882 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 745,614 | 0 | 0 | 0 | For |
Institutional-manager reports, all 307 managers: 104,349,145 for, 1,228,633 against, 6,083 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Acadia Pharmaceuticals Inc.’s own tally for this item (“the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, which was ratified by the following vote”): 157,409,378 for, 3,319,736 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, which was ratified by the following vote:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 96 asset managers below reported 53,156,437 for, 496,232 against, 16,375 abstained, 88,571 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 14,866,415 | 0 | 0 | 0 | For |
| Vanguard | 14,738,657 | 14 | 0 | 0 | For |
| State Street | 5,651,683 | 2,649 | 0 | 0 | For |
| Fidelity | 3,475,543 | 0 | 0 | 0 | For |
| First Trust | 3,177,047 | 0 | 0 | 0 | For |
| TIAA | 1,141,112 | 0 | 0 | 0 | For |
| Charles Schwab | 1,051,680 | 0 | 0 | 0 | For |
| Dimensional | 1,000,882 | 0 | 0 | 0 | For |
| MFS | 621,810 | 0 | 0 | 0 | For |
| Invesco | 609,164 | 0 | 0 | 0 | For |
| John Hancock | 542,429 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 537,427 | 0 | 0 | 0 | For |
| Voya | 445,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 426,213 | 0 | 0 | Against |
| T. Rowe Price | 419,234 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 365,176 | 0 | 0 | 0 | For |
| Equitable | 279,870 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 279,264 | 0 | 0 | 0 | For |
| Jackson National | 230,730 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 203,782 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 180,000 | 0 | 0 | 0 | For |
| Prudential/PGIM | 164,947 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 162,935 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 158,292 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 149,600 | 0 | 0 | 0 | For |
Showing the 25 largest of 96 asset managers. All 96 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 171,086,205 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 8.69% |
| 2 | Vanguard | 8.61% |
| 3 | State Street | 3.30% |
| 4 | Fidelity | 2.03% |
| 5 | First Trust | 1.86% |
| 6 | TIAA | 0.67% |
| 7 | Charles Schwab | 0.61% |
| 8 | Dimensional | 0.59% |
| 9 | MFS | 0.36% |
| 10 | Invesco | 0.36% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 25.19% |
| 2 | State Street | 4.79% |
| 3 | RTW INVESTMENTS, LP | 4.18% |
| 4 | BlackRock | 2.88% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.03% |
| 6 | Palo Alto Investors LP | 1.67% |
| 7 | Point72 | 1.15% |
| 8 | PICTET ASSET MANAGEMENT SA | 1.08% |
| 9 | Frazier Life Sciences Management, L.P. | 0.84% |
| 10 | Charles Schwab | 0.70% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Baker Bros. Advisors LP | 43,356,806 | — | Proxy statement (DEF 14A), table as of February 17, 2026 |
| Julian C. Baker | 43,356,806 | — | Proxy statement (DEF 14A), table as of February 17, 2026 |
| Stephen R. Biggar | 43,253,930 | — | Proxy statement (DEF 14A), table as of February 17, 2026 |
| BlackRock | 21,550,921 | — | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 15,153,957 | — | Form 13F, quarter ended March 31, 2026 |
| State Street | 8,332,771 | — | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 3,464,689 | — | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 3,155,160 | — | Form 13F, quarter ended March 31, 2026 |
| Point72 | 2,605,316 | — | Form 13F, quarter ended March 31, 2026 |
| Renaissance Technologies | 1,724,196 | — | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 171,086,205 shares outstanding, as reported by Acadia Pharmaceuticals Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Acadia Pharmaceuticals Inc.'s shareholder meeting held May 29, 2026, in the 2025-2026 proxy season, 378 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,534 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Acadia Pharmaceuticals Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Acadia Pharmaceuticals Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Acadia Pharmaceuticals Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Acadia Pharmaceuticals Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Acadia Pharmaceuticals (ACAD) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/acadia-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.